Eli Lilly And Co's LLY tirzepatide (10 mg and 15 mg) achieved superior weight loss compared to placebo at 72 weeks of treatment in results from SURMOUNT-2.
The study met both co-primary and key secondary objectives for tirzepatide compared to placebo for both estimands.
Mounjaro (tirzepatide) generated Q1 sales of $568.5 million.
Those taking tirzepatide lost up to 15.7% (34.4 lb. or 15.6 kg) of body weight for the efficacy estimand.
The trial evaluated 938 adult participants with obesity and type 2 diabetes.
Related: Eli Lilly Says Inventory For Diabetes Mounjaro Is Available, Probably Ending Shortage.
For the efficacy estimand, participants taking tirzepatide achieved average weight reductions of 13.4% (29.8 lb. or 13.5 kg) on 10 mg and 15.7% (34.4 lb. or 15.6 kg) on 15 mg compared to placebo (3.3%, 7.0 lb. or 3.2 kg).
Additionally, 81.6% (10 mg) and 86.4% (15 mg) of people taking tirzepatide achieved at least 5% body weight reduction, the other co-primary endpoint, compared to 30.5% of those taking a placebo.
Tirzepatide also met all key secondary objectives, which included a reduction in A1C and other cardiometabolic parameters.
Lilly expects regulatory action as early as late 2023.
Price Action: LLY shares are up 2.26% at $384.79 on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
